Linda Kessler

2.8k total citations · 1 hit paper
38 papers, 1.1k citations indexed

About

Linda Kessler is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Linda Kessler has authored 38 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 15 papers in Oncology and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Linda Kessler's work include Acute Myeloid Leukemia Research (6 papers), Advanced Breast Cancer Therapies (6 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). Linda Kessler is often cited by papers focused on Acute Myeloid Leukemia Research (6 papers), Advanced Breast Cancer Therapies (6 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). Linda Kessler collaborates with scholars based in United States, France and Spain. Linda Kessler's co-authors include Pingda Ren, Lian‐Sheng Li, Jeff Kucharski, Matthew R. Janes, Rasmus Hansen, Tess Ely, Yi Liu, Matthew P. Patricelli, Sarah J. Firdaus and Anjali Babbar and has published in prestigious journals such as Science, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Linda Kessler

38 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State

2016 530 citations Matthew P. Patricelli, Matthew R. Janes et al. Cancer Discovery profile →

Peers

Countries citing papers authored by Linda Kessler

Since Specialization

Citations

This map shows the geographic impact of Linda Kessler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linda Kessler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linda Kessler more than expected).

Fields of papers citing papers by Linda Kessler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Linda Kessler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linda Kessler. The network helps show where Linda Kessler may publish in the future.

Co-authorship network of co-authors of Linda Kessler

This figure shows the co-authorship network connecting the top 25 collaborators of Linda Kessler. A scholar is included among the top collaborators of Linda Kessler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Linda Kessler. Linda Kessler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Anti-PD1 prolongs the response of PI3K and farnesyl transferase inhibition in HRAS- and PIK3CA-mutant head and neck cancers 2025 ·Neoplasia ·(unknown), Sankar Jagadeeshan, (unknown), (unknown), Manu Prasad, (unknown), (unknown), Noam Erez, (unknown), (unknown), (unknown), Irit Allon, Luc G.T. Morris, Gloria H. Su, Hai Wang, Ari J. Rosenberg, Linda Kessler, Francis Burrows, Moshe Elkabets	1
2	Combined Use of Ziftomenib and Selinexor Is Effective in NPM1 Mutant Acute Myeloid Leukemia 2024 ·Blood ·(unknown), Md. Hafiz Uddin, (unknown), (unknown), Amro Aboukameel, Husain Yar Khan, (unknown), Jay Yang, Gregory Dyson, Steven Buck, Asfar S. Azmi, Lisa Polin, Francis Burrows, Linda Kessler, Jaroslaw P. Maciejewski, Suresh Kumar Balasubramanian	2
3	Abstract 1071: Tipifarnib synergizes with TKIs in clear cell renal cell carcinoma models 2023 ·Cancer Research ·Jovylyn Gatchalian, Linda Kessler, (unknown), Francis Burrows, Shivani Malik	1
4	Abstract B024: KO-2806, a next-generation farnesyltransferase inhibitor, potentiates the antitumor activity of cabozantinib in clear cell renal cell carcinoma models 2023 ·Molecular Cancer Therapeutics ·Jovylyn Gatchalian, Linda Kessler, (unknown), (unknown), Francis Burrows, Shivani Malik	1
5	Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma 2022 ·Oncogene ·(unknown), Marielle E. Yohe, Kai Pollard, Angelina V. Vaseva, (unknown), (unknown), Fausto J. Rodríguez, John Gross, Amy N. Allen, Xiaolin Wan, Romel Somwar, Karisa C. Schreck, Linda Kessler, Jiawan Wang, Christine A. Pratilas	28
6	The Menin Inhibitor Ziftomenib (KO-539) Synergizes with Agents Targeting Chromatin Regulation or Apoptosis and Sensitizes AML with MLL Rearrangement or NPM1 Mutation to Venetoclax 2022 ·Blood ·(unknown), (unknown), (unknown), (unknown), Stephan Bohl, Catharina Lahrmann, (unknown), Linda Kessler, Hakim Echchannaoui, Chun‐Wei Chen, Thomas Kindler, Francis Burrows, Matthias Theobald, Daniel Sasca, Scott A. Armstrong, Michael R. Kuehn	1
7	Abstract 4917: Tipifarnib is highly active in HRAS mutant lung squamous carcinoma tumor models 2018 ·Cancer Research ·Linda Kessler, Catherine Scholz, Antonio Gualberto, Yi Liu, Francis Burrows	1
8	Abstract LB-A27: A novel small molecule menin-MLL inhibitor for potential treatment of MLL-rearranged leukemias and NPM1/DNMT3A-mutant AML 2018 ·Molecular Cancer Therapeutics ·Francis Burrows, (unknown), Linda Kessler, Shuangwei Li, Jingchuan Zhang, Patrick P. Zarrinkar, Lian‐Sheng Li, Tomasz Cierpicki, Jolanta Grembecka, Pingda Ren, Yi Liu	11
9	The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib in Acute Myeloid Leukemia and Myelodysplastic Syndromes 2017 ·Blood ·Antonio Gualberto, Catherine Scholz, Matthew R. Janes, Linda Kessler, Azra Raza	4
10	Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State breakdown → 2016 ·Cancer Discovery ·Matthew P. Patricelli, Matthew R. Janes, Lian‐Sheng Li, Rasmus Hansen, Ulf Peters, Linda Kessler, Yuching Chen, Jeff Kucharski, Jun Feng, Tess Ely, Jeffrey H. Chen, Sarah J. Firdaus, Anjali Babbar, Pingda Ren, Yi Liu	530
11	Selective Inhibition of Phosphoinositide 3-Kinase p110α Preserves Lymphocyte Function* 2012 ·Journal of Biological Chemistry ·Lomon So, Sung Su Yea, Jean Oak, Mengrou Lu, (unknown), (unknown), Matthew R. Janes, Linda Kessler, Jeff Kucharski, Lian‐Sheng Li, Michael Martin, Pingda Ren, Katti Jessen, Yi Liu, Christian Rommel, (unknown)	59
12	Abstract A171: A potent and selective PI3K inhibitor, INK1117, targets human cancers harboring oncogenic PIK3CA mutations. 2011 ·Molecular Cancer Therapeutics ·Katti Jessen, Linda Kessler, Jeff Kucharski, Xin Guo, Jocelyn Staunton, Matthew R. Janes, (unknown), (unknown), (unknown), Shunyou Wang, (unknown), (unknown), Levan Darjania, Lian‐Sheng Li, Katrina Chan, (unknown), Pingda Ren, Christian Rommel, Yi Liu	14
13	KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinase 2010 ·European Journal of Pharmacology ·Antonio Montalbán, (unknown), (unknown), (unknown), Russell Dahl, (unknown), (unknown), (unknown), Justin T. Ernst, Andrew R. Gibbs, (unknown), Linda Kessler, Jan O. Lundström, Stephen E. Miller, Hiroshi Nakanishi, Edward Roberts, Eddine Saiah, (unknown), Zhijun Wang, Christopher J. Larson	9
14	Abstract B148: INK128 is a potent and selective TORC1/2 inhibitor with broad oral antitumor activity 2009 ·Molecular Cancer Therapeutics ·Katayoun A. Jessen, Shunyou Wang, Linda Kessler, Xin Guo, Jeff Kucharski, Jocelyn Staunton, (unknown), (unknown), (unknown), (unknown), Lian‐Sheng Li, Katrina Chan, Michael Martin, Pingda Ren, Christian Rommel, Yi Liu	20
15	‘Reverse’ α-ketoamide-based p38 MAP kinase inhibitors 2008 ·Bioorganic & Medicinal Chemistry Letters ·Antonio Montalbán, (unknown), (unknown), (unknown), Russell Dahl, (unknown), (unknown), (unknown), Andrew R. Gibbs, (unknown), Linda Kessler, Jan O. Lundström, Stephen E. Miller, Hiroshi Nakanishi, (unknown), Eddine Saiah, (unknown), Zhijun Wang, Christopher J. Larson	14
16	2,5-Diaminopyrimidines and 3,5-disubstituted azapurines as inhibitors of glycogen synthase kinase-3 (GSK-3) 2008 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), (unknown), Linda Kessler, Jeff Kucharski, Jan O. Lundström, Stephen C. Miller, Hiroshi Nakanishi, Yazhong Pei, Kent E. Pryor, Edward Roberts, (unknown), (unknown), Ján Urban, Zhijun Wang	20
17	The design and synthesis of novel α-ketoamide-based p38 MAP kinase inhibitors 2008 ·Bioorganic & Medicinal Chemistry Letters ·Antonio Montalbán, (unknown), (unknown), (unknown), Russell Dahl, (unknown), (unknown), (unknown), Justin T. Ernst, Andrew R. Gibbs, (unknown), Linda Kessler, Jan O. Lundström, Stephen E. Miller, Hiroshi Nakanishi, Edward Roberts, Eddine Saiah, (unknown), Zhijun Wang, Christopher J. Larson	18
18	Hydrogel wound dressings: where do we stand in 2003? 2003 ·PubMed ·David E. Eisenbud, Heather Hunter, Linda Kessler, Karen Zulkowski	70
19	STAT protein complexes activated by interferon-γ and gp 130 signaling molecules differ in their sequence preferences and trascriptional induction properties 1995 ·Nucleic Acids Research ·Peter Lamb, H. Martin Seidel, (unknown), (unknown), Linda Kessler, Robert B. Stein, Jonathan Rosen	47
20	Rapid Activation of the Interferon-γ Signal Transduction Pathway by Inhibitors of Tyrosine Phosphatases 1994 ·Journal of Interferon Research ·Peter Lamb, Jonathan Haslam, Linda Kessler, H. Martin Seidel, Robert B. Stein, Jonathan Rosen	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact